Combination Treatment for Lung Cancer with STK11 Gene MutationResearch Question:
How well does combination treatment (talazoparib plus avelumab) work in treating patients
with lung cancer?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib
plus avelumab) works in treating patients with non-squamous non-small cell lung cancer
that has an STK11 gene mutation and has come back (recurrent) or is stage IV. Talazoparib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells
to grow and spread. Immunotherapy drugs given as single therapies or in combination
with chemotherapy do not appear to work as well in lung cancer cells with mutations
in the STK11 gene versus those that do not have the mutation. Adding the medicine
talazoparib to the immunotherapy drug avelumab may work better in treating lung cancers
that have an STK11 gene mutation.
Study Reference #: CLUN20004
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amy Jasek
Phone: (585) 273-1912
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search